ProstaLund (PLUN) Q3 2025 earnings summary

Executive summary

• Net sales for Q3 2025 were SEK 2.2 million, down 35.6% year-over-year, with a gross margin improvement to 74.3% from 62.9%.

• Operating loss for Q3 was SEK -2.6 million, an improvement from SEK -4.4 million in Q3 2024.

• For January–September 2025, net sales were SEK 8.1 million, down 17.2% year-over-year, with a gross margin of 73.0%.

• The company is delisting from Nasdaq First North Growth Market, with the last trading day set for October 31, 2025.

• Acute liquidity shortages led to new financing from major shareholders and a SEK 4 million loan.

Financial highlights

• Q3 2025 net sales: SEK 2.2 million (Q3 2024: SEK 3.5 million); 9M 2025: SEK 8.1 million (9M 2024: SEK 9.8 million).

• Q3 2025 operating loss: SEK -2.6 million (Q3 2024: SEK -4.4 million); 9M 2025: SEK -14.0 million (9M 2024: SEK -16.3 million).

• Q3 2025 loss after tax: SEK -2.6 million (Q3 2024: SEK -4.5 million); 9M 2025: SEK -14.2 million (9M 2024: SEK -16.5 million).

• Cash and cash equivalents at September 30, 2025: SEK 0.7 million (September 30, 2024: SEK 12.1 million).

• Cash flow from operating activities for 9M 2025: SEK -11.7 million (9M 2024: SEK -16.1 million).

Outlook and guidance

• Board expects improved cash flow by eliminating listing-related costs and is actively seeking further financing.

• Liquidity remains a challenge, and further cost-cutting may be required.